Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581345 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 study, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 572
- Enrollment target
NCT02581345 is a Phase 3 study that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 572 participants.
The verdict
NCT02581345, a Phase 3 study, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 572 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
Interventions
- BIOLOGICAL M923
- BIOLOGICAL Humira
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-04-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581345
The ClinicalTrials.gov registry entry for NCT02581345 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which M923 is the first listed.
NCT02581345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581345 about?
NCT02581345 is a clinical study titled "Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis". The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
What is the current status of trial NCT02581345?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2015-09. Estimated completion is 2017-04-04.
What interventions are being tested in trial NCT02581345?
The interventions under investigation include: M923 (BIOLOGICAL), Humira (BIOLOGICAL).
Who is sponsoring clinical trial NCT02581345?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.